Advertisement

Nonanticoagulant Actions of Glycosaminoglycans

  • Job Harenberg
  • Benito Casu

Table of contents

  1. Front Matter
    Pages i-viii
  2. Luigi Silvestro, Simona Rizea Savu, P. A. van Veelen, P. L. Jacobs
    Pages 27-46
  3. Günter Huhle, Job Harenberg, Reinhard Malsch, Dieter L. Heene
    Pages 47-58
  4. Walter Jeske, Jawed Fareed, Debra Hoppensteadt, Benito Casu
    Pages 65-87
  5. Alfonso Iorio, Adriano Alatri, Giancarlo Agnelli
    Pages 101-112
  6. Job Harenberg, Reinhard Malsch, Lukas Piazolo, Günter Huhle, Dieter L. Heene
    Pages 113-126
  7. Lukas Piazolo, Job Harenberg, Reinhard Malsch, Dieter L. Heene
    Pages 127-138
  8. Kevin R. Holme, Weisheng Liang, Zicheng Yang, France Lapierre, Patrick N. Shaklee, Lun Lam
    Pages 139-162
  9. Marco Rusnati, D. Coltrini, Pasqua Oreste, Giorgio Zoppetti, Marco Presta
    Pages 171-187
  10. Laura Giorgini, Annamaria Naggi, Giancarlo Ghiselli
    Pages 189-199
  11. Giovanni Camussi, E. Battaglia, Enrico Lupia, G. Montrucchio
    Pages 201-208
  12. Domenico Rotilio, Antonio Tamburro, B. Mariani, O. Lancia, Francesco Peracchia
    Pages 209-225
  13. Piotr Radziwon, J. Schenk, B. Boczkowska-Radziwon, Jawed Fareed, Hans K. Breddin
    Pages 227-233
  14. Susanne Alban, Walter Jeske, Debra Hoppensteadt, Jawed Fareed, Gerhard Franz
    Pages 235-242
  15. Sabine Johann, Reinhold Förster
    Pages 243-248
  16. Giovanni Gambaro, Miriam Barbanti, Egidio Marchi, Bruno Baggio
    Pages 281-286
  17. Back Matter
    Pages 287-295

About this book

Introduction

Prophylaxis and treatment of thromboembolism have made one of the major impacts in medicine. Heparin has widely been used as the most effective drug during the last 50 years. However, its potential side effects have led to the search for equally effective but safer alternatives. At present, the low-molecular-weight heparins are the most promising steps in this direction. Considerable interest has been generated at the same time in exploring other gly­ cosaminoglycans of the nonheparin type for therapeutic use. The existence of these com­ pounds has been known for a long time and substantial information has been gathered on glycosaminoglycans such as heparinsulfate, dermatansulfate, and chondroitinsulfate. Many of these substances are derived from animal or plant sources, and some of them have now been synthesized. The aim of the Fourth Symposium on Glycosaminoglycan Research at Villa Vigoni in Loveno at Lake Comolltaly was to summarize the considerable new information in this field. The articles of the present volume are mainly based on a German-Italian collaboration supported by the Vigoni Program. The selected articles describe many different, nonheparin glycosaminoglycans, some of them already in clinical trials as antithrombotic agents. In particular, the interaction of glycosaminoglycans with some cellular elements of blood, especially leukocytes and platelets, are discussed. New methods for their identification and assays are described and considerable emphasis is placed on the pharmacokinetic aspects of these new compounds. Particularly, some nonanticoagulant activities of the glycosamino­ glycans are discussed in detail.

Keywords

Alzheimer Oligosaccharid biotechnology clinical trial drug pharmacology protein research

Editors and affiliations

  • Job Harenberg
    • 1
  • Benito Casu
    • 2
  1. 1.University of HeidelbergMannheimGermany
  2. 2.G. Ronzoni InstituteMilanItaly

Bibliographic information

Industry Sectors
Pharma
Chemical Manufacturing
Biotechnology
Consumer Packaged Goods